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Like the proverbial wolf in sheep’s clothing, B cells 
can hide the fact that they are harboring a dangerous 
autoreactive immunoglobulin (Ig) by displaying a 
second innocuous Ig. Casellas et al. (page 153) 
now reveal how these fluffy white villains come to 
exist and, rather worryingly, that there are potentially 
large numbers of them in our system.
Transgenic B cells forced to express one self-
reactive Ig allele can switch on a second nonautoreative 
Ig in a process called allelic inclusion. This second Ig 
appears to dilute the autoreactive potential of the 
cell. But it is unknown whether allelic inclusion, 
which defies the “one lymphocyte–one antibody” 
theory of B cell specificity, can occur under normal 
physiological conditions.
Using physiologically normal mice that carried 
one human and one endogenous allele of the Ig 
light chain gene (to enable identification of both), 
Casellas et al. discovered that approximately 10% of 
B cells express two Ig light chain alleles.
The coexpressing cells might arise either because 
allelic exclusion—the permanent switching-off of 
one allele—fails or because the second allele gets 
switched on during receptor editing. Such editing, 
which occurs if the first Ig 
produced by a B cell is discov-
ered to be autoreactive, involves 
switching back on the machinery 
necessary for Ig gene recombi-
nation and expression. With this 
machinery back on, the second 
allele might get activated.
Consistent with this hypo-
thesis, coexpression and auto-
reactivity were correlated. The 
team also sequenced the Ig genes 
in coexpressing cells and found strong evidence that 
editing had occurred. The developmental path of 
these coexpressing cells was slower than that of 
monoexpressing cells, consistent with a necessary 
pause for editing.
The coexpressing B cells, though large in number, 
appear to have their autoreactive tendencies tempered 
by the second Ig allele. However, B cells undergo 
somatic hypermutation at their Ig genes during an 
immune response, suggesting that autoimmune 
disease might be triggered if the innocuous allele is 
edited into oblivion and the wolf is let loose. 
Cell replacement therapy—are MAPCs the answer?
Inherited blood disorders could be a thing of the past. Serafini et al. report on page 129 that multipotent adult 
progenitor cells (MAPCs), produced in vitro from bone marrow, have blood-building capacity in immune-deficient mice.
The full complement of blood cell types arises from hematopoietic stem cells (HSCs) of the bone marrow. The 
ability of these cells to both self-renew and to produce daughter cells capable of any hematopoietic fate makes 
them an attractive resource for cell replacement therapy for blood and immune disorders. However, as with adult 
stem cells from other tissues, long-term culturing of these cells has proven difficult.
MAPCs, on the other hand, can divide seemingly endlessly in culture. These cells, which can give rise 
to multiple cell types, were discovered by chance when Catherine Verfaillie’s group was trying to culture 
another type of adult stem cell. The group now shows that MAPCs can reconstitute hematopoietic 
compartments in vivo just as well as HSCs. Indeed they can even give rise to HSCs themselves.
The team irradiated mice to knock out their immune cells and then injected traceable MAPCs. MAPC-derived 
cells were detectable in the bone marrow, spleen, peripheral blood, and lymph nodes of 
recipient mice and expressed appropriate B, T, and myeloid cell surface markers. 
Furthermore, MAPC-derived B and T cells were shown to be functional by their 
production of immunoglobulin and response to T cell receptor stimulus, respectively.
The team showed that MAPCs also gave rise to functional long-term HSCs. Transfer 
of bone marrow cells from the primary recipient mice into new irradiated mice once 
again led to hematopoietic reconstitution, as did a third round of transfer from these 
secondary mice to tertiary recipients.
None of the recipient mice in the study developed tumors, even though some of the 
MAPCs they received were genetically abnormal because of long-term culturing. Genotyping 
of the recipients’ peripheral blood revealed normal karyotypes, leading Verfaillie to suggest 
that the genetically abnormal MAPCs were somehow cleared by the body.
The risk of tumor development from transplanted embryonic stem cells (ESCs) is an ongoing 
concern for their use in therapy. The potential of long-term culture followed by tumor-free cell 
transfer thus gives MAPCs a therapeutic advantage over both ESCs and HSCs. 
MAPC-derived cells (green) restock the lymph 
nodes of an immunocompromised mouse.
The secret autoreactivity of B cells
A surprisingly large number of B cells 
express two different Ig light chain 
alleles (red and green).